Dramex Interior Finish / Ready Mixed Interior Finish / Water Putty / Block Filler and Primer (Bondex)

Product Description

Dramex Interior Finish was a line of interior finishing and surface preparation products manufactured by Bondex International, Inc. The Dramex product family included several formulations marketed under related names: Dramex Ready Mixed Interior Finish, Water Putty, and Block Filler and Primer. These products were designed for use in residential, commercial, and industrial construction settings, serving a range of surface preparation and finishing functions including filling, priming, and leveling interior walls and masonry surfaces.

Bondex marketed these products throughout much of the postwar construction boom, with documented production spanning from approximately 1948 through 1977. During this period, the construction industry relied heavily on ready-mixed finishing compounds and surface preparation materials, and Bondex positioned the Dramex line as a versatile, cost-effective solution for contractors and tradespeople working on interior finishing projects. The products were sold in powder and ready-mixed formulations and were distributed widely across the United States through building supply retailers and commercial distributors.

Bondex International, Inc. was a subsidiary of RPM International Inc., a specialty coatings and sealants conglomerate. The Dramex line represented one segment of Bondex’s broader portfolio of construction finishing products, which also included other joint compounds and patching materials that have similarly attracted asbestos-related litigation.

Asbestos Content

Litigation records document that Dramex Interior Finish and related Bondex finishing products contained chrysotile asbestos as an ingredient during the years of production from 1948 through 1977. Chrysotile, also known as white asbestos, is a serpentine-form mineral fiber that was widely used during this era as a functional additive in building products. In finishing compounds and fillers, chrysotile fibers contributed to the products’ workability, tensile strength, binding properties, and resistance to cracking after application and drying.

Plaintiffs alleged in civil litigation that Bondex incorporated chrysotile asbestos into the Dramex formulations without adequate warning to end users regarding the health hazards associated with asbestos fiber inhalation. The use of chrysotile as a reinforcing and texturing agent in joint compounds and finishing products was common industry practice during this period, and regulatory oversight of asbestos content in consumer and contractor-grade building materials remained limited through much of the production run.

Chrysotile asbestos is classified as a known human carcinogen by federal regulatory bodies including the Environmental Protection Agency (EPA) and the Occupational Safety and Health Administration (OSHA). Exposure to chrysotile fibers has been associated with the development of asbestosis, mesothelioma, lung cancer, and other asbestos-related diseases. Under the Asbestos Hazard Emergency Response Act (AHERA) framework, friable materials capable of releasing airborne asbestos fibers during disturbance are subject to management and abatement requirements.

How Workers Were Exposed

Workers were exposed to airborne chrysotile asbestos fibers during the normal application and finishing processes associated with Dramex products. Litigation records document that exposure occurred primarily during the mixing, sanding, scraping, and cleanup activities associated with interior finishing work. Industrial workers generally—including those employed in manufacturing facilities, warehouses, commercial construction, and institutional building projects—came into contact with these products as part of their routine work tasks.

Dry mixing of powdered formulations such as Dramex Water Putty and Block Filler and Primer was identified in litigation as a particularly high-exposure activity. When workers combined dry powder formulations with water, or when they sanded dried compound surfaces to achieve a smooth finish, asbestos fibers became airborne and were inhaled. The fine, respirable nature of chrysotile fibers allowed them to remain suspended in indoor air for extended periods, increasing the cumulative exposure dose for workers who performed these tasks repeatedly over the course of a career.

Plaintiffs alleged that workers using Dramex products in enclosed or poorly ventilated spaces—common in interior finishing work—faced elevated exposure levels because fiber dispersal was not adequately controlled. Industrial and commercial workers who used these products on large-scale projects were often exposed across longer durations and in greater quantities than residential users, and litigation records reflect claims from individuals employed in manufacturing plants, institutional facilities, and large commercial construction projects where Bondex Dramex products were specified or used.

Bystander exposure was also documented in litigation. Workers in adjacent trades—including painters, electricians, plumbers, and general laborers—who were present in work areas where Dramex products were being mixed, applied, or sanded were exposed to secondhand fiber release without directly handling the products themselves.

OSHA’s current permissible exposure limit (PEL) for asbestos is 0.1 fibers per cubic centimeter of air (f/cc) as an eight-hour time-weighted average. The exposure standards in place during the Dramex production years from 1948 to 1977 were substantially less protective, and workplace monitoring for asbestos in finishing compound applications was not uniformly conducted during this period.

Documented Trust Fund / Legal Options

There is no active asbestos bankruptcy trust fund established for Bondex International, Inc. or its parent company RPM International Inc. related to Dramex Interior Finish or other Bondex finishing products. Because Bondex and RPM have not filed for asbestos-related bankruptcy reorganization, claims arising from Dramex product exposure are pursued through the civil tort litigation system rather than through an administrative trust fund claims process.

Litigation records document that individuals alleging injury from exposure to Bondex Dramex products have filed civil lawsuits in state and federal courts across the United States. Plaintiffs alleged that Bondex and related corporate entities were liable under theories including negligence, strict products liability, and failure to warn, contending that the company knew or should have known of the hazards associated with asbestos-containing finishing compounds and failed to provide adequate warnings or instructions to users.

Individuals diagnosed with mesothelioma, asbestosis, lung cancer, or other asbestos-related conditions who have a documented history of occupational exposure to Dramex Interior Finish or related Bondex products may have viable legal claims. Because these claims are litigated rather than resolved through a trust fund, outcomes vary based on jurisdiction, the strength of exposure documentation, medical evidence, and other case-specific factors.

Persons who believe they may have been exposed to Dramex products are encouraged to:

• Document their work history thoroughly, including employers, job sites, dates of employment, and the specific products handled or encountered
• Obtain medical evaluation from a physician familiar with asbestos-related disease diagnosis and latency periods
• Consult an attorney experienced in asbestos litigation to evaluate the strength and timing of a potential claim, as statutes of limitations vary by state and begin running from the date of diagnosis or discovery

Family members of deceased workers who used Dramex products may also have grounds to pursue wrongful death claims under applicable state law. Legal consultation should be sought promptly given the time-sensitive nature of asbestos litigation filings.